Clinical trial
Emulation of the Effects of Oral Semaglutide on Cardiovascular Outcomes in Individuals With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease: SOUL Trial
NCT06659718 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Emulation of the Effects of Oral Semaglutide on Cardiovascular Outcomes in Individuals With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease: SOUL Trial
- Lead sponsor
- Brigham and Women's Hospital
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 24, 2024
- Completion date
- February 13, 2025
- Enrollment
- 43,650 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.